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Abstract 
Traumatic brain injury (TBI) is a risk factor for dementia, with studies describing a mixed 
neurodegenerative pathology in late survivors.  However, the mechanisms driving this post-
TBI neurodegeneration remain elusive.  Increasingly, blood brain barrier (BBB) disruption is 
recognized in a range of neurological disorders, including dementias; although little is known 
of the consequences of TBI on the BBB. From the Glasgow TBI Archive autopsy cases of 
single, moderate or severe TBI (n=70) were selected to include a range of survivals from 
acute (10h to 13days) to long-term (1 to 47years) survival, together with age-matched, 
uninjured controls (n=21). Multiple brain regions were examined for fibrinogen (FBG) and 
immunoglobulin G (IgG) immunohistochemistry. Following TBI, 40% of patients dying in 
the acute phase and 47% of those surviving a year or more from injury showed multi-focal, 
abnormal, perivascular and parenchymal FBG and IgG immunostaining localized to grey 
matter, with preferential distribution towards the crests of gyri and deep neocortical layers. In 
contrast, where present, controls showed only limited, localized immunostaining. These 
preliminary data demonstrate evidence of widespread BBB disruption in a proportion of TBI 
patients emerging in the acute phase and, intriguingly, persisting in a high proportion of late 
survivors.  
 
 
 
 
Key words: Traumatic brain injury, chronic traumatic encephalopathy, blood brain barrier, 
fibrinogen. 
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Introduction 
Traumatic brain injury (TBI) represents a major health concern, with 3.5 million cases in the 
United States each year (1).  In addition to the immediate health impacts of the injury, TBI is 
acknowledged as the strongest environmental risk factor for the development of 
neurodegenerative disease, typically reported as Alzheimer’s disease (AD)(2-13) in type or, 
more recently, recognized as chronic traumatic encephalopathy (CTE)(14-16). Corresponding 
to this, autopsy studies in material from patients exposed to either single moderate or severe 
or repetitive mild brain injury reveal a complex of neurodegenerative pathologies including 
pathologies in tau, amyloid-²  and TDP-43, neuronal loss, neuroinflammation and white 
matter degradation (13,15-20). However, the mechanisms driving these late, post-TBI 
neurodegenerative pathologies remain elusive. 
 
Disruption in blood brain barrier (BBB) integrity is increasingly recognized in a variety of 
disorders, including ischemia (21),  multiple sclerosis (22) and neurodegeneration (23, 24). In 
particular, imaging (25) and animal modelling (23, 26) studies in AD suggest BBB 
dysfunction is an early event in the course of disease and may contribute to its pathogenesis, 
perhaps as a result of impaired amyloid-²  clearance or associated neuroinflammation (23,27-
31). Furthermore, neuropathology studies report complex vascular changes associated with 
BBB dysfunction in AD (32-34), with evidence of a correlation between histological evidence 
of BBB leakage and Alzheimer-type pathologies in ‘normal’ ageing (35). 
 
Following TBI, acute phase BBB disruption has been demonstrated in several animal models 
(36-48) though with conflicting data on the time-course of this disruption some studies  
suggesting BBB disruption is short lived, resolving  within hours of injury (36-47), while 
others suggest a more dynamic, biphasic course following injury, with early phase BBB 
disruption at 3-6 hours post injury followed by later, further BBB at 1-3 (38, 48). In support 
of this ‘late’ BBB dysregulation after TBI is the observation of focal immunoglobulin G (IgG) 
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deposition around callosal blood vessels ipsilateral to controlled cortical impact in mice at 3 
months survival from injury (49). 
 
Consistent with observations in animal models, evidence of acute BBB permeability 
following severe TBI in humans is provided by reports of elevations in CSF to serum albumin 
quotient (50-53) and in serum S100²  levels (50-53) after injury. Of note, such evidence of 
acute BBB disruption following TBI might predict a population of patients with poor long-
term outcome (52).  Furthermore, neuroimaging evidence of BBB disruption has been 
reported in patients following TBI, even after clinically mild or moderate injury; in some 
cases persisting for years at the site of focal injury (contusions) and with greater frequency in 
patients with post-traumatic epilepsy (54).  Intriguingly, imaging evidence of BBB disruption 
has been observed in American football participants, independent of clinical evidence of TBI, 
possibly as a result of exposure to ‘sub-concussive’ head impacts(55). 
 
Thus there is evidence from animal models and limited clinical studies of BBB disruption 
following TBI. However, the extent and time course of this TBI-associated BBB disruption in 
humans remains poorly understood. In particular, evidence of BBB disruption at late time 
points post-injury has not been explored. Here, we utilize material from the Glasgow TBI 
Archive to characterize the extent, distribution and temporal dynamics of BBB disruption 
following closed head injury, with respect to age-matched, uninjured controls. 
 
Materials and Methods 
Case Selection and Brain Tissue Preparation 
Ethical approval for this study was granted by the West of Scotland Research Ethics Service. 
From the Glasgow TBI Archive, cases with a history of single moderate or severe TBI aged 
60 years or under at time of death were selected, representing a range of survival times from 
injury to include: acute cases with survival times of 10 hours to <14 days (n=27); intermediate 
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cases with survival times of 14 days to <1 year (n=11); and long-term cases with survival 
times from 1 year to 47 years (n=32). Detailed reports from the original diagnostic 
autopsywere available for all cases , where necessary supplemented by forensic and clinical 
records, and confirmed a clinical history of moderate or severe TBI as defined by Glasgow 
Coma Scale at presentation. Age matched, uninjured controls aged 60 years or under at time 
of death and with no known history of neurological disease or history of TBI (n=21) were 
selected for comparison.  Across the cohorts, post-mortem delays were comparable (p>0.05 in 
all comparisons across cohorts; Student t-test). Demographics, clinical data and detail on 
neuropathology findings at the original autopsy for each cohort are presented in Table 1. 
 
At the time of the original diagnostic autopsy, whole brains were immersion fixed in 10% 
formal saline for a minimum of 3 weeks then dissected, sampled following a standardized 
block selection protocol and processed to paraffin using standard techniques. Paraffin tissue 
blocks from a coronal slice of the cerebral hemispheres at the mid-thalamic level were 
identified for analysis to include: the thalamus; corpus callosum with adjacent cingulate and 
superior frontal gyri; hippocampus at the level of the lateral geniculate nucleus extending 
through the entorhinal cortex, collateral sulcus and fusiform gyrus; and the insular cortex. 
From these tissue blocks 8µm sections were prepared for Hematoxylin and eosin staining and 
immunohistochemistry. 
 
Hematoxylin and eosin staining 
Hematoxylin and eosin (H&E) staining was performed on sections from all tissue blocks.  
Slides were deparaffinized in xylene and rehydrated to water followed by immersion for 10 
minutes in hematoxylin (Mayer’s, Leica Microsystems, Wetzlar, Germany).  After rinsing and 
immersion in Scott’s tap water substitute (Leica Microsystems, Wetzlar, Germany), slides 
were differentiated in 1% acid alcohol and rinsed.  The sections were then immersed in 25% 
aqueous eosin Y solution (TCS Biosciences, Buckingham, UK) for 5 minutes, rinsed, then 
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dehyrated, cleared and coverslipped. 
 
Immunohistochemistry 
Following deparaffinization and rehydration, sections were immersed in 3% aqueous H2O2 
(15 minutes) to quench endogenous peroxidase activity. Antigen retrieval was performed via 
microwave pressure cooker for 8 minutes in preheated 0.1M Tris EDTA buffer. Subsequent 
blocking was achieved by applying 50µL of normal horse serum (Vector Labs, Burlingame, 
CA, USA) per 5 mL of Optimax buffer (BioGenex, San Ramon, CA, USA) for 30 minutes. 
Incubation with the primary antibody was then performed for 20 h at 4°C. Polyclonal rabbit 
anti-human antibodies for fibrinogen (FBG) and immunoglobulin G (IgG) (Dako, Carpinteria, 
CA, USA) were utilized at dilutions of 1:17,500 and 1:10,000 respectively. A biotinylated 
secondary antibody was then applied for 30 minutes followed by avidin biotin complex as per 
the manufacturer’s instructions (Vectastain Universal Elite kit, Vector Labs, Burlingame, CA, 
USA). Finally, visualization was achieved using the DAB peroxidase substrate kit 
(VectorLabs, Burlingame, CA, USA) followed by counterstaining with haematoxylin. Known 
positive tissue sections were run in parallel with test sections in all antibody runs in addition 
to sections with primary antibody omitted as standard controls for antibody specificity.  All 
sections were viewed using a Leica DMRB light microscope (Leica Microsystems, Wetzlar, 
Germany). In addition, sections were scanned at 20x using a Hamamastu Nanozoomer 2.0-HT 
slide scanner, with the images viewed via the SlidePath Digital Image Hub application (Leica 
Microsystems, Wetzlar, Germany). 
 
Analysis of Immunohistochemical Findings 
All observations were conducted blind to demographic and clinical data by two independent 
observers (JH, AY). Anatomically distinct regions were defined for assessment to include the 
neocortical grey matter of the cingulate gyrus; cingulate sulcus; superior frontal gyrus; 
parahippocampal gyrus; collateral sulcus; fusiform gyrus and insular cortex. A subanalysis of 
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neocortical grey matter was performed by dividing the cortex into superficial (layers I-II), mid 
(layers III-IV) and deep layers (V- VI). In addition, the white matter of the midline and lateral 
extent of the corpus callosum and internal capsule; hippocampal sectors CA1-4 and the 
thalamus (sub-divided into medial, intermediate and lateral regions) were assessed. Each 
anatomical region was reviewed and a semi-quantitative assessment of the frequency and 
intensity of immunoreactivity determined as absent (0), sparse (1), moderate (2) or extensive 
(3). Representative examples of immunohistochemical findings and the corresponding semi-
quantitative score are shown in Figure 1. 
 
Statistical analysis 
All data were analyzed using Minitab (v.16; Minitab Inc.). The Chi-square Test was used to 
assess differences in data between and within cohorts. 
 
Results 
Fibrinogen Immunoreactivity After TBI 
Controls 
In uninjured controls, where present, FBG immunoreactivity was observed in a predominantly 
perivascular distribution, highlighting small vessels throughout the neuropil. In addition, 
occasional, sparse immunoreactive neurons and glia were observed. In the overwhelming 
majority of controls (17 of 21), this FBG immunoreactivity was limited (score 0 or 1) (Figure 
2a) and localized (Figure 3). In the remaining 4 controls, localized foci of moderate (score 2) 
levels of FBG immunoreactivity were observed in single tissue blocks; in two cases localized 
to the thalamus, one to the fusiform gyrus and the last to the superior frontal gyrus (Figure 4). 
Causes of death in these controls with localized, moderate FBG immunoreactivity were 
mixed; one sudden death in epilepsy, one sudden death of cardiac origin, one sepsis with 
multi-organ failure and one pneumonia. 
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Acute TBI survival 
In material from patients dying acutely following TBI (10 hours to <14 days survival), in 
addition to perivascular FBG immunoreactivity, regions of more confluent, diffuse 
immunostaining were also present (Figure 2b). Indeed, in contrast to the typically limited 
abnormal FBG immunoreactivity observed in controls, in this acute TBI survival cohort 88% 
(p<0.001; ChiSq) of cases showed at least one anatomical region with moderate (score 2) or 
extensive (score 3) FBG immunoreactivity. Further, in contrast to the localized pathology in 
controls, following TBI increased FBG immunoreactivity often appeared multifocal, 
involving 2 or more regions in 11 out of 27 (40%) acute survival cases (Figure 3). Of the 
regions examined, moderate or extensive FBG immunoreactivity was detected most 
frequently in material from the cingulate and superior frontal gyri (16 cases), followed by 
thalamus (12 cases), medial temporal lobe (11 cases) and insular cortex (6 cases) (Figure 4). 
Within the neocortical material (cingulate, superior frontal, fusiform and parahippocampal) 
there was evidence of preferential anatomical distribution, with moderate or extensive FBG 
immunoreactivity more evident in the crests of gyri than in the depths of the adjacent sulci 
(Figure 5a) in both cingulate and medial temporal lobe cortical regions. Further, there was 
localization of abnormal FBG immunoreactivity towards mid (layers 3 and 4) and deep 
(layers 5 and 6) cortical layers rather than superficial (layers 1 and 2) cortical layers (Figure 
2b; Figure 5b) in all cortical regions. Notably, only one acute survival case showed focal, 
moderate FBG immunoreactivity in the hippocampal formation (sector CA2), with no acute 
survival case showing more than localized, limited FBG immunoreactivity in the corpus 
callosum, similar to controls. No localization to a particular thalamic sub-region was evident, 
neither was the observed abnormal FBG staining localized to focal pathologies of TBI. 
 
Intermediate TBI survival 
Similar to material from patients dying acutely following TBI, regions of moderate or 
extensive FBG immunoreactivity were present in a greater number of intermediate (>2 weeks 
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to 1 year post-TBI) TBI survival patients than in controls, with 7 of 11 (64%; p=0.004 ChiSq) 
demonstrating at least one anatomical sub-region with moderate or high FBG 
immunoreactivity; showing multifocality in 4 of these cases (Figure 3). Again, material from 
the region of the cingulate and superior frontal gyri most frequently showed increased staining 
(6 cases), followed by medial temporal lobe (4 cases), thalamus (2 cases) and insular cortex (2 
cases) (Figure 4). As in acute survival material, there was a predilection for gyral crests over 
sulcal depths in the cingulate gyrus and medial temporal lobe and, though the small number of 
cases precludes formal statistical assessment, a trend towards preferential staining in mid to 
deep rather than superficial neocortical layers in all cortical regions (Figures 5a and 5b). 
There was no notable FBG immunoreactivity in the white matter of the corpus callosum, with 
only 2 cases showing more than mild staining in the hippocampus. 
 
Long-term TBI survival 
Once again, a higher proportion of long-term survival cases showed evidence of increased 
FBG immunoreactivity when compared to matched, non-injured controls (Figure 2c), with at 
least one anatomical region showing moderate or extensive FBG immunoreactivity in 22 of 
32 cases (69%) (p<0.001; ChiSq). Again, multifocality was common, being present in 15 of 
the long term survival cases (47%) (Figure 3); this increased staining most frequent in 
material from the medial temporal lobe (17 cases), followed by cingulate and superior frontal 
gyri and thalamus (14 cases each) and insular cortex (5 cases) (Figure 4). As in acute and 
intermediate cases, a preferential distribution to the crests of gyri over depths of sulci was 
evident (Figure 5a). Further, within the crests of gyri, FBG immunoreactivity was greater in 
the mid and deeper layers than the superficial layers of the cortex. Thus, in the superior 
frontal gyrus 56% showed moderate or high FBG immunostaining in the deeper layers 
compared to just 12% in the superficial layers (p=0.001; ChiSq) (Figure 5b) this pattern was 
reflected in all cortical regions assessed.  In the medial temporal lobe 40% showed high FBG 
immunostaining in the deep layers compared to 18% in the superficial layers (p=0.1379; 
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ChiSq).  In contrast to earlier survival time points and controls, 23% (p=0.023; ChiSq) of 
cases in this long-term survival cohort showed hippocampal FBG immunoreactivity greater 
than mild in at least one hippocampal sector, though with no clear preferential distribution to 
any particular sector. In keeping with this widespread increased FBG immunoreactivity in 
these long-term survival cases, 58% showed increased thalamic staining, versus just 10% of 
controls (p=0.001; ChiSq). However, once again, no increase in FBG immunoreactivity was 
detected in material from the corpus callosum. 
 
Immunoglobulin G Immunoreactivity After TBI 
Controls 
Observations in the IgG stained material corroborated the observations in material stained for 
FBG (Figure 2d). Thus, at all survival points and in controls the extent and distribution of IgG 
immunoreactivity was comparable to FBG immunoreactivity with regards to greater 
perivascular and confluent, diffuse staining IgG immunoreactivity in a proportion of TBI 
cases at all survivals when compared to controls. Specifically, IgG immunoreactivity in the 
control cohort was limited with only 4 of 21 (19%) cases displaying moderate IgG 
immunoreactivity (score of 2); in two cases this was localised to the superior frontal gyrus, 
one case localised to the thalamus and one to the fusiform gyrus.  Again, no multifocality was 
observed and causes of death included sudden death in epilepsy (n=2), drug overdose (n=1), 
and pneumonia (n=1). 
 
Acute TBI survival  
The acute TBI survival cohort demonstrated moderate or high IgG immunoreactivity in at 
least one anatomical sub-region in 63% of cases (p<0.005 ChiSq), with multifocality present 
in 10 out of 27 (37%). Of the regions examined, moderate or extensive IgG immunoreactivity 
was detected most frequently in material from the medial temporal lobe (10 cases), followed 
by the cingulate/superior frontal gyri and the thalamus (8 cases) then the insular cortex (2 
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cases).  As with FBG immunoreactivity there was evidence of preferential anatomical 
distribution, with moderate or extensive IgG immunoreactivity more evident in the crests of 
gyri than in the depths of the adjacent sulci and in the mid to cortical deep layers when 
compared to the superficial cortical layers.   
 
Intermediate TBI survival 
Following intermediate survival from TBI, regions of moderate or widespread IgG 
immunoreactivity were present in a greater number than in controls with 6 of 11 (54%; 
p=0.05 ChiSq) demonstrating at least one anatomical sub-region with moderate/high IgG 
immunoreactivity, with multifocality present in 45%. 
 
Long-term TBI survival 
The long-term survival TBI cohort demonstrated 71% (23 out of 32 cases) of moderate/high 
IgG immunoreactivity in at least one anatomical sub-region (p=0.0002; ChiSq).  Multifocality 
again was common with 14 of the 32 long-term TBI cases (43%) showing immunoreactivity 
in 2 or more sub-regions.  Increased IgG staining was most frequent in the medial temporal 
lobe (13 cases each), followed by cingulate/ superior frontal gyri and thalamus (12 cases) and 
insular cortex (3 cases).  The pattern and distribution of IgG immunoreactivity echoed the 
results in fibrinogen prepared material, with preferential distribution to the crests of gyri over 
the depths of sulci in both cingulate gyri and hippocampal gyri, and greater IgG 
immunoreactivity observed in the mid and deeper layers versus the superficial neocortical 
layers.   
 
Association of BBB disruption with TBI-associated pathologies 
Reviewing H&E stained sections from the multiple tissue blocks examined for 
immunohistochemical evidence of BBB disruption confirmed anticipated BBB disruption in 
association with acute, focal hemorrhagic pathologies, in addition to more widespread and 
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diffuse BBB disruption independent of focal pathology. Specifically, in material from acute 
TBI survivors 21 TBI-associated focal hemorrhagic or contusional lesions were observed 
across 13 of the 27 cases, with virtually all (12 of 20 lesions) displaying some degree of 
extravascular fibrinogen immunoreactivity in the surrounding parenchyma. However, in the 
majority of these cases (9 of 13; 69%) BBB disruption was not confined to the region of focal 
pathology, with evidence of widespread, diffuse BBB also present in the remaining tissue 
blocks. Notably, in the 14 acute survival TBI cases without focal hemorrhage or contusion, 12 
(86%) also displayed high fibrinogen immunoreactivity in at least one region examined. 
 
In material from patients surviving beyond the acute phase of injury evidence of healed 
hemorrhages or contusions, with histological features consistent with lesions dating from the 
time of the original TBI, were present in 2 of 11 intermediate survival (comprising 6 
individual lesions) and 8 of 32 long-term survival cases (comprising 12 distinct lesions). 
While not as extensive as observed in relation to focal hemorrhages or contusions in acute 
survivors, some evidence of BBB disruption was observed in the immediate locality of all 6 
lesions in material from intermediate survivors. In contrast, evidence of focal BBB disruption 
in association with healed hemorrhages or contusions was less frequently observed in material 
from long-term survivors, with just 6 of 12 lesions associated with abnormal FBG or IgG 
immunoreactivity. Of note, both of the intermediate survival cases and all 8 of the long-term 
survival cases with BBB disruption in association with focal pathologies also displayed more 
widespread, diffuse BBB disruption remote from focal pathology. Further, 6 of 9 intermediate 
and 15 of 24 long-term survival cases showing no evidence of focal hemorrhagic or 
contusional pathology in the material examined displayed evidence of high FBG 
immunoreactivity in at least one region. 
 
In addition to these focal hemorrhagic and contusional pathologies, histological evidence of 
diffuse hypoxic/ ischemic injury, microgliosis and/or astroglisosis in varying stages of 
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evolution was identified in a proportion of TBI cases across all survivals. No correlation 
between these TBI-related pathologies and evidence of BBB disruption was observed. 
 
 
 
Discussion 
Here we demonstrate histological evidence of widespread, diffuse blood-brain barrier (BBB) 
disruption in survivors of a single moderate or severe TBI when compared to non-injured 
controls. Notably, evidence of increased and widespread extravascular immunoreactivity for 
fibrinogen (FBG) and immunoglobulin G (IgG) was observed not only in material from 
patients dying in the acute phase post-injury, but also in a high proportion of those surviving 
many years after injury. As such, these data raise the possibility that a single moderate or 
severe TBI is responsible for immediate and long-lasting alterations in BBB function 
following injury, which might contribute to post-TBI neurodegeneration.  
 
Under normal conditions, the plasma proteins fibrinogen (340kDa) and IgG (150kDa) do not 
cross the BBB. However, we observed widespread, multifocal, perivascular and parenchymal 
FBG and IgG deposition in approximately half of patients dying within the first 2 weeks 
following a single moderate or severe TBI; indicating that these proteins had crossed the BBB 
in the acute phase following injury. Similar acute BBB leakage has been identified in various 
animal models of TBI, as revealed by the presence of either extravasated serum proteins or 
intravascularly injected labels in the brain parenchyma (36-44, 46, 56, 57) following injury. In 
these models often extensive, acute BBB leakage can be observed in the absence of 
hemorrhage, consistent with our observations in this human, autopsy-acquired tissue. 
 
As regards possible structural correlates of this acute BBB disruption, ultrastructural studies 
in animal models of TBI have identified a variety of alterations in vascular endothelia in the 
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acute phase following injury, including the formation of vacuoles, craters and microvilli (47, 
57-59) some of which were later identified in human TBI (60, 61).  These very rapid changes 
in vascular structure and function have been attributed to a range of mechanisms such as 
direct perturbation of the vessels by mechanical forces, including the immediate disruption of 
vascular endothelial cells. Additional, secondary insults following injury might also be 
detrimental to normal endothelial integrity and function, including acute rises in arterial 
pressure or intravascular thrombus formation (45, 56, 57).  Finally, active physiological 
changes have also been described in both animals and humans following TBI, including 
increased transendothelial vesicular transport with otherwise intact tight junctions (47, 59, 61, 
62) as well as alterations to other components of the BBB, such as early astrocyte disruption 
and swelling (45, 58).  
 
Studies suggest that these acute BBB disruptions may confer worse long-term outcome 
following TBI clinically (52), although the relative role of this pathology is unknown. Indeed, 
acute BBB opening after TBI may simply be one of many common pathological features of a 
more severely injured brain, which collectively contribute to poor outcome.  Nonetheless, 
specific deleterious mechanisms of BBB disruption following TBI may include influx of fluid 
together with chemical and protein mediators promoting vasogenic edema, disruption in the 
normal pathways to clear toxic metabolites, and a failure to deliver normal metabolites vital 
for function. In turn, the temporal course and relative contribution of these various 
consequences of BBB disruption may differ with the mode of injury.  
 
Although data from animal models are reported as showing evidence of a biphasic BBB 
opening (38, 48), in the present study we identified no clear evidence of defined phases of 
BBB disruption across our various survival cohorts, in particular in the acute phase. 
Nevertheless, the possibility of distinct phases of BBB disruption following injury cannot be 
entirely excluded, with the diverse and heterogeneous nature of post-mortem TBI cases with 
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varying intercurrent illnesses, survival times and causes of injury conceivably masking such 
an observation. Nonetheless, studies specifically directed at understanding the underlying 
mechanisms of this BBB dysfunction over time might reveal important potential therapeutic 
targets with defined windows of opportunity. 
 
While a degree of acute BBB disruption was anticipated, the number of cases, often with 
extensive BBB disruption following long-term survival from TBI was, nonetheless, 
surprising. Specifically, extensive, multifocal, extravascular FBG and IgG deposition was 
observed in approximately half of those surviving a year or more from injury in our cohort. 
Notably, clearance of large soluble proteins from the brain parenchyma occurs via convective 
bulk flow of interstitial fluid over the order of hours to days, or more rapidly via reverse 
transcytosis, such as occurs with IgG (63). Thus, the observation of soluble plasma proteins in 
the brain parenchyma of patients exposed to TBI more than a year prior to death is consistent 
with on-going BBB disruption, rather than evidence of protein deposited at the time of injury 
and not cleared in the intervening period. 
 
The pattern and distribution of chronic BBB disruption post-TBI was more frequently 
localized to the grey matter of the neocortical ribbon and deep grey nuclei, with a preferential 
distribution in the former to mid and deeper cortical layers over superficial layers and the 
crests of gyri over depths of sulci. This pattern indicates preferential vulnerability in specific 
locations within a more global and diffuse process, rather than a heterogeneous multifocal 
pathology. Undoubtedly this observation presents challenging and interesting data given the 
contrast with current descriptions of aspects of the neuropathology of post-TBI 
neurodegeneration and CTE where localization of tau pathologies to the depths of sulci is 
reported.  However, at present, the pathologies of CTE are provisional, therefore should be 
taken as such.  More research into these conflicting observations should be carried out in the 
future.  
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Notably our data demonstrate  no association with evidence of widespread and diffuse BBB 
disruption and the presence of other TBI-associated pathologies. Specifically, BBB disruption 
was not localized to areas of focal TBI pathologies, such as contusions or hemorrhages. 
Further, there was no correlation between diffuse and widespread BBB disruption and diffuse 
ischemic pathology.  Nevertheless, the number of cases and necessary heterogeneity in 
pathologies in this cohort limit the ability to determine whether specific diffuse primary or 
secondary pathologies in the acute phase can account for later patterns of BBB disruption. 
However, this will be worthy of exploration using larger post-mortem cohorts and, possibly, 
animal models. 
 
In recent years, the chronic clinical and neuropathological sequelae of TBI have been 
increasingly reported, with particular attention paid to the association of TBI survival with 
increased risk of progressive neurodegenerative disorders, specifically CTE (14-16).  
Neuropathological examination of autopsy acquired material from patients with survival 
greater than a year from a single moderate or severe TBI reveals an increased frequency of 
neurodegeneration-associated pathologies when compared to material from matched controls, 
including amyloid-²  plaques, neurofibrillary tangles, inflammation and white matter 
degradation (13, 17, 18, 20). Notably, the role of the BBB in neurodegeneration is of 
increasing interest, with evidence indicating that changes to the brain’s microvasculature may 
actively contribute to development of AD pathology (for detailed review see (23)). Various 
micro-vascular changes have been reported in AD including changes to vessel structure and 
density (33), BBB breakdown and leakage (32, 35), and secretion of potentially neurotoxic 
factors from the vascular endothelium (64). While the extravasation of serum proteins such as 
fibrinogen has also been shown to correlate with the presence of Alzheimer-type 
pathology(35), the cause or effect relationship between alterations in the vasculature and 
associated neurodegenerative pathologies is not well defined. However, increasing clinical 
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and experimental data suggest vascular changes can occur early and may contribute to states 
of hypoperfusion promoting neuronal injury (23, 33, 65, 66). Studies to evaluate potential 
associations between BBB breakdown and other pathologies associated with 
neurodegenerative disease will be an important future consideration.  
 
Perhaps the most widely studied aspect of BBB with regards to AD, is its role in the clearance 
and sequestration of amyloid beta to the peripheral circulation (28, 67-69).  Interestingly, 
individuals with high serum fibrinogen have been shown at greater risk of AD (70, 71).  
Fibrinogen was also shown to accelerate inflammation and neurovascular damage in a mouse 
mode of AD (72). While the number of cases described in the present study precludes analysis 
of multiple co-variants, the interplay and temporal relationship between BBB disruption and 
subsequent progressive neurodegenerative pathologies will be an important direction for 
future investigation. 
 
Conclusion 
Here we present the first preliminary data indicating that after just a single moderate or severe 
TBI there is neuropathological evidence of widespread, diffuse, multifocal BBB disruption in 
just under one half of patients, even after many years of survival from injury. Given that 
vascular dysfunction may be an important contributor to neurodegenerative disorders, acute 
and chronic BBB alterations post-TBI will be important to examine in this context.  
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Table Legend 
Table 1. Demographic and clinical data for all groups. 
 
 
 
Figure Legends: 
Fig. 1 Representative examples of the patterns of FBG immunoreactivity encountered 
(a) Section from the superior frontal gyrus of a 47 year old male TBI patient who died 1 year 
following a fall. No abnormal FBG immunoreactivity is present (score of 0). (b) Limited, 
faint perivascular FBG immunoreactivity (score of 1) from the superior frontal gyrus of a 60 
year old male TBI patient who died 16 years after a road traffic accident. (c) More 
widespread, moderate perivascular FBG immunoreactivity (score of 2) in the superior frontal 
gyrus of a 60 year old male TBI patient who survived 10 hours after a fall. (d) Extensive 
perivascular and adjacent parenchymal FBG immunoreactivity (score of 3) in the superior 
frontal gyrus of a 50 year old male TBI patient who survived 1 year after an assault.  (e)  
Extensive perivascular FBG immunoreactivity in thalamic region of a 60 year old male TBI 
patient who survived 8 days after a fall.  (f) Limited perivascular FBG immunoreactivity in 
parahippocampal region of a 56 year old female TBI patient who survived 24 hours after a 
road traffic accident.  Scale bars = 1mm and apply to all corresponding images. 
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Fig. 2 Representative images of FBG and IgG immunoreactivity following TBI and in 
controls. Absence of FBG immunoreactivity in the superior frontal gyrus of a 46 year old 
male with no history of TBI. (b) Extensive FBG immunoreactivity in the superior frontal 
gyrus, with preferential distribution of staining to the mid and deep cortical layers, in a 20 
year old male TBI patient who survived 2 days following an assault. Extensive FBG (c) and 
IgG (d) immunoreactivity in the adjacent sections from the superior frontal gyrus of a 60 year 
old male TBI patient who survived 18 years following a fall. Scale bars = 1mm and apply to 
all corresponding images. 
 
Fig. 3 Extent of abnormal FBG immunoreactivity following TBI at varying survivals 
versus controls. Whilst moderate or extensive FBG immunoreactivity was an uncommon 
observation in controls, occurring in just 4 of 21 cases (19%), it was a frequent observation 
following TBI at all survival time points assessed, being present in 88%, 62% and 69% of 
acute, intermediate and long-term survival cases respectively. Furthermore, in controls 
abnormal FBG immunostaining was restricted to single anatomical regions, in contrast to the 
often multifocal pathology in material following TBI. (*p<0.005; **p<0.001; Chi-square TBI 
cohort v control fibrinogen positivity). 
 
Fig. 4 Regional distribution of FBG immunoreactivity following TBI versus controls. At 
all survival intervals and in each region analyzed there was evidence of BBB disruption 
following TBI, evidenced by moderate/ extensive FBG immunoreactivity, in a higher 
proportion of TBI survivors than matched, non-injured controls in material from the (a) 
cingulate/superior frontal gyri, (b) thalamus (c) hippocampus and (d) insular cortex. 
(*p<0.05; **p<0.01; ***p<0.005; +p<0.0005; ++p<0.0001; Chi-square TBI cohort v control) 
 
Fig. 5 Neocortical distribution of FBG following TBI. (a) Across all survival time points 
there was a clear preferential distribution of abnormal FBG immunoreactivity to the crests of 
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gyri when compared to the depths of sulci, as illustrated here for the superior frontal gyrus 
versus the adjacent cingulate sulcus (*p<0.01; **p<0.001; Chi-square sulcus versus gyrus). 
(b) Further, within the neocortical grey there was preferential distribution of abnormal 
staining to the mid (layers 3 and 4) and deep (layers 5 and 6) cortical layers when compared 
to superficial layers (layers 1 and 2). (+p<0.01; ++p<0.005; Chi-square deep versus 
superficial cortical layers). 
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Table 1. 
 
 
 
 
 
 TBI: Acute 
Survival (n=27) 
TBI: Intermediate 
Survival (n=11) 
TBI: Long-Term 
Survival (n=32) 
Controls  
(n=21) 
Mean age (Range) 44.4 years 
(9-60) 
32 years 
(17-56) 
46.3 years 
(19-60) 
34.3  years  
(14-60) 
 
Males 17 
(63%) 
11 
(100%) 
31 
(97%) 
12  
(57.1%) 
Mean PM Delay (Range) 56.1 hours  
(3-240) 
 
74.7 hours  
(26-192) 
 
65.5 hours  
(9-184.5) 
 
71.6 hours 
(12-144)  
Mean Survival Interval (Range) 69.3 hours 
(6-216)  
72.8 days 
(14-279)  
7.8  years 
(1-47)  
Not applicable 
Cause of 
TBI 
Fall 15 
(56%) 
2 
(18%) 
15 
(47%) 
Not applicable 
(No history TBI) 
RTA 7 
(26%) 
5 
(42%) 
5 
(16%) 
Assault 4 
(15%) 
3 
(25%) 
8 
(25%) 
Unknown 1 
(4%) 
1 
(8%) 
4 
(12%) 
Cause of 
Death 
Head injury 25(93%) 4 (33%) 0 0 
Bronchopneumonia 2(7%) 4(33%) 7(22%) 1(4.8%) 
ARDS 0 2(17%) 1(3%) 0 
Pulmonary 
thromboembolism 
0 1(8%) 0 0 
Heart disease 0 0 6 (19%) 4(16.67%) 
Alcohol related 0 0 2(6%) 0 
Pyelonephritis 0 0 1(3%) 0 
Multi-organ failure 0 0 1(3%) 0 
GIT hemorrhage 0 0 1(3%) 0 
Polytrauma 0 0 1(3%) 0 
Drug overdose 0 0 0 4(16.67%) 
SUDEP   7(22%) 8(38.1%) 
Pulmonary edema 0 0 1(3%) 0 
Septicemia 0 0 0 2(8.3%) 
Inhalation of gastric 
contents 
0 0 0 2(8.3%) 
Unknown 0 0 4(12%) 0 
TBI 
 
Skull fracture 20(74%) 6(54%) 15(47%) 0 
Pathologies DAI 11(40%) 10(91%) 6(19%) 0 
 Brain Swelling 13(48%) 2(18%) 0 0 
 SDH 20(74%) 4(36%) 13(41%) 0 
 EDH 0 0 3(9%) 0 
 SAH 15(56%) 0 1(3%) 0 
Key: TBI = traumatic brain injury; SUDEP = sudden unexpected death in epilepsy; GIT = gastrointestinal tract; ARDS 
= acute respiratory distress syndrome; RTA = road traffic accident;  DAI = Diffuse Axonal Injury; SDH = Subdural 
hemorrhage; EDH = Extradural hemorrhage; SAH = Subarachnoid hemorrhage. 
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